Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arvinas, Inc.
Canaan Has Capital For Start-Ups With Eye On New Twists On Traditional Modalities In Pharma
VC partner Colleen Cuffaro talked to Scrip about how the investment firm plans to direct investment in biopharma and raising capital in a challenging environment.
Olema Flies Flag For SERDs, Planning Phase III Trials As Rivals Stumble
Several factors differentiate Olema Oncology’s lead drug candidate from the SERD herd, says its CEO Sean Bohen, as the firm looks to partner the ‘ready-for-Phase III multibillion-dollar asset.’
Arvinas And Pfizer’s Protein Degrader Shows Mixed Results In Breast Cancer
The frontrunner in the new protein degrader class has shown lackluster Phase II results in breast cancer, but Arvinas hopes for success in less heavily pre-treated patients in Phase III.
Novartis Changing Of The Guard Continues As R&D Chief Bradner Exits
A smooth handover hints at an amicable departure for Jay Bradner, but also gives CEO Vas Narasimhan the chance to refresh strategy with a new team.
- Large Molecule
- Other Names / Subsidiaries
- Arvinas LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.